IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
IGM Biosciences, Inc. (IGMS)
Last igm biosciences, inc. earnings: 3/26 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. “We are pleased to have exceeded our enrollment target of 110 patients in our randomized study of 3 mg/kg of aplitabart plus FOLFIRI and bevacizumab in second line colorectal cancer,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “While we are still scheduling first doses for a few patients, we expect that final enrollment in this clinical trial will exceed 120 patients. We are also pleased that we have completed enrollment in the first dose cohort of our clinical trial of imvotamab in severe rheumatoid arthritis.” Pipeline Updates Aplitabart (DR5 agonist) Clinical development of aplitabart advances. Enrollment target exceeded in ongoing randomized
Show less
Read more
Impact Snapshot
Event Time:
IGMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGMS alerts
High impacting IGM Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IGMS
News
- IGM Biosciences, Inc. (NASDAQ: IGMS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.MarketBeat
- IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- IGM Biosciences to Present at the 2024 RBCCM Global Healthcare ConferenceGlobeNewswire
IGMS
Earnings
- 5/8/24 - Beat
IGMS
Sec Filings
- 5/8/24 - Form 8-K
- 5/8/24 - Form 10-Q
- 4/26/24 - Form ARS
- IGMS's page on the SEC website